Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the
treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; …

Inhibitors of PD-1 signaling have revolutionized cancer therapy. PD-1 and PD-L1 antibodies
have been approved for the treatment of cancer. To date, therapeutic PD-1 inhibitors have …

The immune checkpoints are regulatory molecules that maintain immune homeostasis in
physiological conditions. By sending T cells a series of co-stimulatory or co-inhibitory signals …

Breast cancer is the most common invasive tumor in women and the second leading cause
of cancer-related death. Nanomedicine raises high expectations for millions of patients as it …

Programmed death ligand 1 (PD-L1) plays a key role in glioblastoma multiforme (GBM)
immunosuppression, vitality, proliferation, and migration, and is therefore a promising target …

Drug conjugates, including antibody-drug conjugates, are a step toward realizing Paul
Ehrlich's idea from over 100 years ago of a “magic bullet” for cancer treatment. Through …

The targeted delivery of potent cytotoxic molecules into cancer cells is considered a
promising anticancer strategy. The design of clinically effective antibody–drug conjugates …

Breast cancer has historically been considered a non-immunogenic tumor. Multiple studies
over the last 10–15 years have demonstrated that a small subset of breast cancers is …

Antibody drug conjugates (ADCs) are an emerging class of therapeutics that consist of a
cytotoxic agent linked covalently to an antibody, which is directed toward a specific cell …